This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
At the recent meeting of the Southern Section of the Triological Society in Orlando, Fla, Paul Levine, MD, presented his experience at the University of Virginia, Charlottesville, with esthesioneuroblastoma. He and coworkers Copley McLean, MD, and Robert Cantrell, MD, have had the unusual opportunity to treat 26 patients over the past 25 years. Group 1 patients (treated prior to 1975) were managed with 5,000 rad of radiation therapy preoperatively, followed by resection using a Weber-Ferguson approach. Group 2 patients were managed more aggressively with a similar preoperative radiation protocol, but surgery was performed using a craniofacial approach. Those patients with stage-C disease (tumor extension beyond the nasal cavity and the sinuses or the presence of metastases) were treated with cyclophosphamide and vincristine sulfate prior to the radiation therapy.
Of the eight determinate patients in group 1, only three are alive more than 20 years following their therapy. The tumors of
MILLER RH. Management of Esthesioneuroblastoma: A 25-Year Experience. Arch Otolaryngol Head Neck Surg. 1986;112(5):487. doi:10.1001/archotol.1986.03780050011001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: